Search Results - "Krege, John"

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study) by Brandes, Jan Lewis, Klise, Suzanne, Krege, John H, Case, Michael, Khanna, Rashna, Vasudeva, Raghavendra, Raskin, Joel, Pearlman, Eric M, Kudrow, David

“…To address the need for long-term lasmiditan data, the GLADIATOR study evaluated the safety (primary) and efficacy (secondary) of lasmiditan for the…”
Get more information

Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis by Díez-Pérez, Adolfo, Marin, Fernando, Eriksen, Erik F., Kendler, David L., Krege, John H., Delgado-Rodríguez, Miguel

“…In randomized clinical trials (RCTs) with teriparatide, the number of patients with incident hip fractures was small and insufficiently powered to show…”
Get full text

Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies by Langdahl, Bente L., Silverman, Stuart, Fujiwara, Saeko, Saag, Ken, Napoli, Nicola, Soen, Satoshi, Enomoto, Hiroyuki, Melby, Thomas E., Disch, Damon P., Marin, Fernando, Krege, John H.

“…Teriparatide significantly reduces fracture rates in clinical trials; however, those study populations were relatively restricted and included too few patients…”
Get full text

A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density by Recker, Robert R., Benson, Charles T., Matsumoto, Toshio, Bolognese, Michael A., Robins, Deborah A., Alam, Jahangir, Chiang, Alan Y, Hu, Leijun, Krege, John H, Sowa, Hideaki, Mitlak, Bruce H., Myers, Stephen L.

“…ABSTRACT Sclerostin, a SOST protein secreted by osteocytes, negatively regulates formation of mineralized bone matrix and bone mass. We report the results of a…”
Get full text

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN by Krege, John H, Rizzoli, Paul B, Liffick, Emily, Doty, Erin G, Dowsett, Sherie A, Wang, Jianing, Buchanan, Andrew S

“…We assessed the safety profile of lasmiditan, a selective 5-HT receptor agonist without vasoconstrictive activity being developed as an acute therapy for…”
Get more information

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Knievel, Kerry, Buchanan, Andrew S, Lombard, Louise, Baygani, Simin, Raskin, Joel, Krege, John H, Loo, Li Shen, Komori, Mika, Tobin, Joshua

“…Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed…”
Get more information

Teriparatide in patients with osteoporosis and type 2 diabetes by Schwartz, Ann V, Pavo, Imre, Alam, Jahangir, Disch, Damon P, Schuster, Dara, Harris, Jennifer M, Krege, John H

“…Abstract Despite evidence for higher fracture risk, clinical effects of osteoporosis treatments in type 2 diabetes (T2D) are largely unknown. Post hoc analyses…”
Get full text

PINP as an aid for monitoring patients treated with teriparatide by Tsujimoto, Mika, Chen, Peiqi, Miyauchi, Akimitsu, Sowa, Hideaki, Krege, John H

“…Abstract Biochemical markers of bone turnover may be useful aids for managing patients with osteoporosis. A 12-month, phase 3, multicenter trial of Japanese…”
Get full text

Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study by Dempster, David W, Zhou, Hua, Recker, Robert R, Brown, Jacques P, Recknor, Christopher P, Lewiecki, E Michael, Miller, Paul D, Rao, Sudhaker D, Kendler, David L, Lindsay, Robert, Krege, John H, Alam, Jahangir, Taylor, Kathleen A, Melby, Thomas E, Ruff, Valerie A

“…ABSTRACT There has been renewed interest of late in the role of modeling‐based formation (MBF) during osteoporosis therapy. Here we describe early effects of…”
Get full text

Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis by Eriksen, Erik F, Keaveny, Tony M, Gallagher, Eileen R, Krege, John H

“…Abstract Teriparatide is a skeletal anabolic treatment for patients with osteoporosis at high risk for fracture. Because adequate clinical trials have not yet…”
Get full text

Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates by Krege, John H, Gilsenan, Alicia W, Komacko, John L, Kellier‐Steele, Nicole

“…ABSTRACT The phase 3 trials of the bone anabolic drug teriparatide were prematurely terminated because of a preclinical finding of osteosarcoma in rats treated…”
Get full text

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study by Reuter, Uwe, Krege, John H, Lombard, Louise, Gomez Valderas, Elisa, Krikke-Workel, Judith, Dell-Agnello, Grazia, Dowsett, Sherie A, Buse, Dawn C

“…A significant proportion of triptan users exhibit an insufficient response or inadequate tolerability to a triptan, and some may develop a contraindication…”
Get more information

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study by Lipton, Richard B., Lombard, Louise, Ruff, Dustin D., Krege, John H., Loo, Li Shen, Buchanan, Andrew, Melby, Thomas E., Buse, Dawn C.

“…Background Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT 1F receptor agonist…”
Get full text

Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS) by Soen, Satoshi, Fujiwara, Saeko, Takayanagi, Ryoichi, Kajimoto, Kenta, Tsujimoto, Mika, Kimura, Shuichi, Sato, Masayo, Krege, John H., Enomoto, Hiroyuki

“…Objective: The Japan Fracture Observational Study (JFOS), a prospective observational study, investigated the real-world effectiveness of daily teriparatide to…”
Get full text

Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant by Doty, Erin G., Krege, John H., Pohl, Gerhardt, Case, Michael, Dowsett, Sherie A., Tepper, Stewart J.

Get full text

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials by Loo, Li Shen, Ailani, Jessica, Schim, Jack, Baygani, Simin, Hundemer, Hans-Peter, Port, Martha, Krege, John H.

“…Objective To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background While…”
Get full text

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks by Tepper, Stewart J., Vasudeva, Raghavendra, Krege, John H., Rathmann, Suchitrita S., Doty, Erin, Vargas, Bert B., Magis, Delphine, Komori, Mika

“…Objective To identify factors predicting response (2‐hour headache pain freedom or most bothersome symptom freedom) to lasmiditan based on individual patient…”
Get full text

Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial by Komori, Mika, Ozeki, Akichika, Tanji, Yuka, Kamiki, Eriko, Krege, John H., Li, Lily Qian, Suzuki, Shiho, Shibata, Mamoru, Takeshima, Takao

“…Background The objective of this analysis was to gain new insights into the patient characteristics and other factors associated with lasmiditan usage and…”
Get full text

The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials by Doty, Erin G., Hauck, Paula M., Krege, John H., Komori, Mika, Hake, Ann M., Dong, Yan, Lipton, Richard B.

“…Background In controlled clinical trials, compared with placebo, a significantly greater proportion of participants using lasmiditan to treat a migraine attack…”
Get full text

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN) by Loo, Li Shen, Plato, Brian M, Turner, Ira M, Case, Michael G, Raskin, Joel, Dowsett, Sherie A, Krege, John H

“…We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. SAMURAI and SPARTAN were double-blind, placebo-controlled…”
Get full text